However, because mutational signatures reflect ongoing genomic instability, which is common in tumors and recognized as a targetable vulnerability of cancer, mutational signatures could help better stratify patients for targeted therapies e.g. immunotherapy for MMR-deficient tumors [66, 67]. This evidence concerns the gene MRC1 and cancer.